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Gamma-hydroxybutyrate (GHB, sodium 
oxybate) is a compound related to neuromodulator 
gamma-aminobutyric acid (GABA), emerging as a 
recreational drug of abuse and as a rape drug. GHB-
related emergencies have dramatically increased in 
the 1990s, but a decrease is observed since 2000. 
We describe the case of an acute GHB intoxication 
in a 28-year-old male who fell unconscious after 
ingestion of a mouthful of an unknown beverage, 
and required medical support for 2 days. A cocaine 
abuse was also detected by preliminary toxicologi-
cal screening, but the clinical presentation was not 
typical of cocaine intoxication.
A simple liquid-liquid extraction was used for 
quantitation of GHB, followed by disilyl-derivatiza-
tion and analysis in selective ion monitoring (SIM) 
mode by gas chromatography-mass spectrometry 
(GC-MS), using GHB-d6 as internal standard.
High concentrations of GHB were detected in urine 
(3020 mg/L) and gastric contents (71487 mg/L) at 
admission. After a 6-hours delay, GHB was still present 
in urine at 2324 mg/L and in blood at 43 mg/L.
The clinical symptoms of cocaine intoxication 
were diminished by GHB consumption, and the 
cerebral scan was modiﬁ ed. Attention must thus be 
paid to acute intoxications with surprising clinical 
symptoms, and GHB has probably to be added to 
the preliminary toxicological screening.
Data available regarding GHB are briefly 
reviewed, and our results are compared with 
previously published reports of non-fatal GHB 
intoxication.
INTRODUCTION
Gamma-hydroxybutyrate (GHB, sodium oxybate), a 
compound structurally related to the human depressant 
neurotransmitter gamma-aminobutyric acid (GABA) 
(Figure 1), is naturally present at nanomolar concentra-
tions in the mammalian brain (1). It has been shown to 
act on speciﬁ c receptors, called GHB receptors (2), and 
also on GABA-B receptors (3;4). 
At low doses (about 10 mg/kg), it induces anxiolysis, 
somnolence, amnesia, hypotonia; whereas it is hyp-
notic with powerful sedative properties at higher doses 
(30 to 60 mg/kg) (5;6). GHB might lead to euphoria, 
dependence, and shows an unfortunate effectiveness 
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as a “drug-facilitated sexual assault” agent (“rape drug”) 
(7;8).
GHB, isolated in 1874 (9), was ﬁ rst synthesized by 
Laborit in the early 1960s (10). GHB was then used for 
years in Europe and the United States as an anaes-
thetic agent, as an hypnotic (11) and in the treatment 
of alcohol withdrawal (12). It was originally considered 
as a food supplement, sold in health food stores as a 
sleep aid, as a weight loss drug and as muscle enhancer. 
GHB was alleged to increase production of growth 
hormone (13;14), which lead to its abuse by bodybuild-
ers as a steroid alternative when steroid use became 
illegal in the late 1980s (15). 
In the 1990s, GHB spread from the sports world over 
the club world (16;17). Due to its stimulant, anxiolytic 
and euphoric effects at low doses, GHB became a 
popular drug of abuse in clubs, where it is often called 
“liquid ecstasy”, “liquid X”, “G”, “Grievous Bodily Harm”, 
“liquid E”, “Georgia Home Boy”, “gamma-oh”, “easy lay”, 
etc. Consequently, GHB-related emergencies in the US 
increased dramatically from 56 cases in 1994 to about 
Figure 1.  Metabolic pathway of GHB and related substances.
 GHB is almost completely metabolized by GHB dehydrogenase (GHB-DH) into succinic semialdehyde, which is then converted by 
succinic semialdehyde dehydrogenase (SSA-DH) into succinic acid that enters Krebs cycle and leads to the production of CO2 + 
H2O. GHB has thus no speciﬁ cally identiﬁ able oxidation products.
 Conversion of GHB into neurotransmitter gamma-aminobutyric acid (GABA) is ensured by GHB-DH and GABA transaminase.
 Gamma-butyrolactone (GBL) is converted in vivo into GHB by lactamase, which simply breaks open the lactonic ring. 1,4-bu-
tanediol (1,4-BD) is oxidized in 4-OH-butaldehyde by ADH (alcohol dehydrogenase), and then converted into GHB by aldehyde 
dehydrogenase (ALDH).
 
5000 in 2000 (18), but a decrease was observed when 
GHB was scheduled in 2000 (19-21). 
Since the United Nation’s decision to put GHB under 
control in March 2001, GHB has been a controlled sub-
stance in most European Union member states. The 
European Medicines Agency (EMEA) has designated it 
as an “Orphan Medicinal Product” in February 2003, and 
delivered a marketing authorisation, valid throughout 
the EU, in October 2005 (22), for the treatment of 
cataplexy in adult patients with narcolepsy (23;24). GHB 
is now legally available for this indication, under control-
led conditions, in most of the EU member states as in 
the US (Xyrem®) (22). There are important differences 
in GHB seizures in Europe, but the global trend seems 
to be stabilization or decrease in GHB abuse since 2002-
2003 (25-27). In Belgium, the trend in GHB use in regard 
of total drug abuse in recreational settings varied be-
tween 1% to 2% from 2002 to 2005 (28). 
Gamma-butyrolactone (GBL) and 1,4-butanediol 
(1,4-BD), converted in vivo to GHB (Figure 1), are not 
controlled substances (e.g. industrial solvents) (29). 
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Easily available on the Internet, they are often used for 
GHB preparation or as GHB substitute (30;31), with an 
increasing risk of adverse effects due to increased bio-
disponibility (32-34). 
Difﬁ culties to ﬁ nd one’s personal dose range (an 
extra 10% can lead from euphoria to vomiting) (35), 
concentrations variability of available powders and 
solutions, confusion between GHB, 1,4-BD and GBL, and 
frequent dilution with alcohol are associated with an 
elevated occurrence of adverse effects, although it has 
been shown that there are minimal pharmacokinetic 
interactions between GHB and ethanol (36). 
The half-life of GHB is approximately 30 min and 
GHB can be totally excreted from the body within 10-
12 h. GHB is often undetectable in plasma after 6–8 h, 
in living patients (37;38).
Moreover, GHB is an endogenous compound and 
post-mortem production might be signiﬁ cant and be-
come a severe artefact, particularly in blood (39-41). 
Urine, easily available and less susceptible to post-mor-
tem modification, is the recommended sample 
(41;42).
In forensic cases (i.e. overdose, death, driving under 
the inﬂ uence (DUI), sexual assault), case history, delay 
of analysis, post-mortem interval (39;43), storage 
(42;44), clinical presentation (levels of sedation or coma, 
agitation, combativeness, self-injurious behaviours, etc.) 
have to be considered for an accurate interpretation of 
the toxicological ﬁ ndings (45).
CASE HISTORY
A 28-year-old white male was found in comatose 
on the public way, in the lateral recovery position, on a 
saturday night. He was transported to an emergency 
department. Friends reported that he had vigilance 
disorders 10 minutes after ingestion of a mouthful of 
an unknown beverage. Clinical presentation did not 
agree with morphinic or cocainic intoxication. The pa-
tient was in an ethylic state. The subject’s eyes were 
bloodshot, with a strong bilateral miosis and ﬁ xed pupils. 
He was haemodynamically stable with a pulse of 66 
bpm and a blood pressure of 120/80 mm Hg. His res-
piratory rate was of 19 breaths per minute. 
Propofol and remifentanil were administered upon 
arrival at the emergency department to allow patient’s 
intubation, and to calm him down. Urine, blood and 
gastric aspiration were collected for toxicology. Gastric 
lavage and activated charcoal administration were per-
formed. A cerebral CT scan showed a cerebral oedema 
and a suspicion of meningeal haemorrhage. The patient 
did not show any trace of cutaneous or intravenous 
injection. Electrocardiogram and cardio-pulmonary ex-
amination were normal. Blood tests showed a slight 
elevation of white blood cell count (15440/mm³) with 
normal leukocyte differential. Electrolyte proﬁ le was 
normal. A mild respiratory acidosis (pH 7.29) was 
present, and lactic acid was elevated (26.4 mg/dL). Renal, 
liver and pancreatic function tests were normal.
Toxicology screening on Abbott Axsym® and Roche 
Cobas Integra 400®, based on “Fluorescence Polarization 
Immunoassay” (FPIA), were performed on urine, blood 
and gastric aspiration. 
Cocaine metabolite was found highly positive in 
urine, above the limit of linearity (LOL: 5.0 mg/L). Pres-
ence of cocaine in urine (benzoylecgonine >1.2 mg/L) 
and blood (benzoylecgonine: 142 μg/L) was conﬁ rmed 
by GC-MS. Benzoylecgonine was detected positive in 
gastric aspiration by HPLC-DAD, but not quantiﬁ ed. 
Ethanol was found positive at 1.60 g/L on Abbott Ax-
sym®, based on “Radiative Energy Attenuation” (REA) 
technology. 
Urine1 and serum2 “FPIA”-screening were negative 
for salicylates, acetaminophen, barbiturates, benzodi-
azepines, tricyclic antidepressants, cannabinoids, opiates 
and amphetamines. GC-MS and HPLC-DAD techniques 
conﬁ rmed these ﬁ ndings. Gastric aspiration screening 
was also negative, after treatment with Subtilisin A 
(Sigma-Aldrich Chemie Gmbh, Steinheim, Germany).
The patient was transferred to the Intensive Care 
Unit, where he was extubated rapidly. At day +1, the 
patient was still complaining about persistence of mod-
erate pulsatile holocranian cephalgias. He also reported 
a total amnesia of the past events. Electroencephalo-
gram was normal. The patient was discharged 2 days 
after arrival.
1  Limits Of Quantitation (LOQ) for urine (in our lab). 
 Cocaine metabolites : 0.10 mg/L; barbiturates : 0.12 mg/L; 
benzodiazepines : 0.20 mg/L; tricyclic antidepressants : 40.0 
μg/L; salicylates : 5.0 mg/L; cannabinoids : 13.0 μg/L; opiates : 
0.06 mg/L; amphetamines : 0.50 mg/L
2  Limits Of Quantitation (LOQ) for serum (in our lab).
 Tricyclic antidepressants : 75.0 μg/L; salicylates : 5.0 mg/L; 
acetaminophen : 1.0 mg/L; barbiturates : 0.03 mg/L; benzodia-
zepines : 0.003 mg/L.
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Due to intoxication history and clinical evolution 
(46;47), a speciﬁ c determination of GHB was performed 
afterwards on the available samples, i.e. urine obtained 
at admission and 6 hours after admission, serum ob-
tained 6 hours after admission (blood sample at admis-
sion was insufﬁ cient), and gastric contents obtained at 
admission. 
To measure GHB in our patient’s samples, a conven-
tional technique was used : liquid-liquid extraction 
followed by gas chromatography coupled with mass 




GHB sodium and GHB-d6 sodium were purchased 
from Cerilliant (Texas, USA) as 1.0 mg/ml solutions in 
methanol (as salt). Methanol and acetonitrile were 
analytical High Performance Liquid Chromatography 
(HPLC) grade (both purchased from Lab-Scan Analytical 
Sciences, Dublin, Ireland). Ethyl acetate was Normapur 
analytical reagents from BDH-Prolabo-VWR. The deri-
vatization reagent was a BSTFA/TMCS mix (99:1, V/V). 
BSTFA was N,O-bis(trimethylsilyl)-triﬂ uoroacetamide 
for gas chromatography from Merck KGaA (Damstadt, 
Germany). TMCS was trimethylchlorosilane for synthe-
sis from Merck Schuchardt OHG (Hohenbrunn, Ger-
many). 0.1N sulphuric acid solution used for extraction 
was prepared by dilution of sulphuric acid min 95%, 
purchased from VEL (Leuven, Belgium).
Instrumentation 
The automated injector was a Combi/Liquid PAL 
System Autosampler from CTC Analytics – Interscience. 
The GC model was an Interscience Thermo Electron 
Corporation Trace GC Ultra Gas Chromatograph with a 
split/splitless injector. The carrier gas was He (purity 
grade N60, 99.9999%) and the column used was a VF-5 
MS capillary column ((5%-Phenyl)-dimethylpolysiloxane, 
30m x 0.25 mm i.d., 0.25 μm ﬁ lm thickness) (Factor Four 
Capillary Column from Varian, The Netherlands). A 
Thermo Electron Corporation DSQ Mass Selective Detec-
tor was coupled to the GC for quantitative analysis. 
Methods
Extraction
The extraction procedure was the same for urine, 
serum and gastric aspiration. Gastric contents were 
centrifuged. All samples were stored at -18°C (44). Each 
assay included a blank and an in-house quality control 
of 30 mg/L. To be in the linearity range of the GC, the 
patient’s samples were appropriately diluted with bi-
distilled water.
A 6-points calibration curve was built for urine, se-
rum and gastric liquid, respectively. Twenty μl of blank 
matrix (fresh urine, fresh serum or fresh gastric liquid) 
were spiked with appropriate volume of GHB working 
solutions in methanol to obtain concentrations of 2.5, 
5.0, 10.0, 20.0, 40.0 and 80.0 mg/L. In order to take into 
consideration the “matrix effect” in the extraction pro-
cedure, pure methanol was added to the mix to system-
atically reach the volume of 40 μl of methanol in every 
sample. 
Similarly, 20 μl of the samples were vortex mixed 
with 40 μl of methanol. 10 μl of GHB-d6 methanolic 
solution (40 mg/L) were added as internal standard, 
followed by 200 μl of H
2
SO4 0.1N and vortex mixed. 
Ethyl acetate (4 ml) was added, and the compounds 
were extracted for 10 minutes on a rotating mixer, fol-
lowed by a centrifugation at 2500 rpm for 5 minutes. 
The supernatant organic layer was transferred to a clean 
extraction tube and evaporated to dryness under N
2
 
gentle ﬂ ow at 30 °C. The extracts were derivatized with 
30 μl of a BSTFA/TMCS mix (99:1, V/V) for 30 min at 
70°C. After cooling, the samples were transferred in GC 
vials.
Analytical conditions
A 1 μl aliquot of the sample was automatically in-
jected into the column, through which was applied a 
constant ﬂ ow of 1.8 mL/min of carrier gas. Splitless 
mode was used for injection (Splitless time 1 min), and 
split vent remained opened all analysis long. The injec-
tor temperature was 230°C, and the oven temperature 
was initially set at 60°C, hold for 2 min, increase to 
150°C at 10°C/min, then increase to 300C at 30°C/min, 
and hold at 300°C for 5 min. The GC-MS transfer line 
temperature was set at 300 °C and the ion source at 
250 °C. The classical electron impact mode at 70 eV 
was used for the ionization of the compounds. The 
electron multiplier was operated at 1370V and the 
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detector gain set at 1.105. Dwell times were set at 50 
ms for each ion and the total scan time was of 0.27 sec. 
Prior to all analyses the MS was tuned with the auto-
mated DSQ Tune programme. 
Pure derivatized GHB and GHB-d6 were injected to 
deﬁ ne analytical conditions. Data were recorded in full 
scan mode, for the identiﬁ cation of GHB and GHB-d6 
speciﬁ c ions and to identify appropriate retention time 
(Figure 2). Retention times were established at 8.57 min 
for derivatized GHB-d6 and 8.62 for derivatized GHB. 
Ions selected for Single Ion Monitoring (SIM) of GHB 
were m/z 233, 204 and 117, and GHB-d6 speciﬁ c ion 
was m/z 239 (Figure 3), as previously described (48;51) 
(underlined ions were used for quantitation).
RESULTS
For all samples, a weighted (1/x²) linear regression 
analysis of the ratio “GHB peak area to internal stand-
ard (GHB-d6) peak area” was performed. The 6-points 
calibration curves were linear over the concentration 
range assayed (2.5 to 80 mg/L), and regression ﬁ ts (R²) 
were excellent (R²=0.9975 for urine, R²=0.9971 for 
serum and R²=0.9982 for gastric contents). Independ-
ently of the matrix, coefﬁ cients of variation were of less 
than 9% and accuracy ranged between 90.1% and 
104.2%. Limit of detection (LOD) was determined as 1 
mg/L, and limit of quantitation (LOQ) was deﬁ ned as 
the lowest calibrator point, i.e. 2.5 mg/L.
 
 
Figure 2:  GC-MS proﬁ le of a derivatized GHB-spiked urine.
 Retention times were established at 8.57 min for derivatized GHB-d6 (internal standard) and 8.62 for derivatized GHB. (RT 8.77 = 
urea; RT 9.10 = phosphate).
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Figure 3: Mass spectra of the trimethylsilyl derivative of GHB (GHB-di-TMS) and deuterated-GHB (GHB-d6-di-TMS as internal standard).
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Three-hydroxybutyrate (BHB), an endogenous beta-
isomer of GHB known to have a very similar ion frag-
mentation pattern to GHB (52), had a retention time 
more than 1 min shorter than GHB, and did not interfere. 
Moreover, ion ratios were different between GHB and 
BHB. 
Urine collected at admission was positive for GHB 
at the concentration of 3020 mg/L, a high concentration 
not frequently reported in the literature (Figure 4). Urine 
collected 6 hours after admission was still positive, at 
the concentration of 2324 mg/L.
In spite of the short half-life of GHB in humans 
(37;53), serum obtained 6 hours after admission was 
still positive for GHB, at the concentration of 43 mg/L. 
Gastric contents collected at admission were posi-
tive for GHB at concentration of 71487 mg/L.
DISCUSSION
The combination of a stimulant drug (cocaine) and 
a depressant drug (GHB) leads to a clinical feature quite 
difﬁ cult to manage for emergency physicians. The an-
tagonism of effects between the 2 drugs, moreover 
associated with an alcoholic state, can explain this 
situation. 
We found a high concentration of GHB in urine at 
admission (3020 mg/L), and the urine concentration 
was still elevated after 6 hours, at the concentration of 
2324 mg/L. Despite the short half-life of GHB in body, 
serum was still positive after 6 hours, at the concentra-
tion of 43 mg/L. The concentration measured in gastric 
contents (71487 mg/L) is comparable to the value re-
ported by Kintz et al (70800 mg/L) (54). 
CONCLUSION
This paper reports on a case of an acute intoxication 
with GHB, together with cocaine. This is, to our knowl-
edge, one of the most serious GHB overdose reported 
in Belgium, after Louagie et al in 1997 (55) and Segers 
et al in 2002 (56). Moreover, GHB concentration in urine 
is a high concentration not frequently reported in the 
medical literature (Figure 4). 
Figure 4:  Patient’s GHB concentration in urine, in comparison with data reported in the literature, i.e. 53 cases > 10 mg/L (48;54;56-67).
 Fifty-one per cent of reported cases are below 1000 mg/L (27 cases on 53), 75% of reported cases are below 2000 mg/L (40 cases 
on 53), and 85% of reported cases are below 3000 mg/L (45 cases on 53). 
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What is quite interesting is that the clinical presen-
tation was not typical of cocaine intoxication, even if 
cocaine and benzoylecgonine have been ingested. 
The clinical symptoms of cocaine intoxication were 
diminished by GHB consumption, and the cerebral scan 
was modiﬁ ed. Attention must thus be paid to acute 
intoxications with surprising clinical symptoms, and 
GHB has probably to be added to the preliminary toxi-
cological screening.
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